Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN SARANTOPOULOS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1861495343
CMS profile
175298
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$90,134.59

121 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $38,625.92 64
PFIZER INC. $22,722.86 21
Regeneron Healthcare Solutions, Inc. $17,216.81 26
Astellas Pharma US Inc $10,735.74 7
ARRAY BIOPHARMA INC $720.00 1
AstraZeneca Pharmaceuticals LP $90.36 1
Eisai Inc. $22.90 1

Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN SARANTOPOULOS

NPI 1861495343 · CMS profile ID 175298

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861495343?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN SARANTOPOULOS, NPI 1861495343, CMS profile ID 175298. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861495343?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOHN SARANTOPOULOS, NPI 1861495343, CMS profile ID 175298. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861495343?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOHN SARANTOPOULOS, NPI 1861495343, CMS profile ID 175298, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861495343?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

121 matching records · $90,134.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 121 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 121.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $377.5006/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156066 CMS
Regeneron Healthcare Solutions, Inc. $27.0006/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156071 CMS
Regeneron Healthcare Solutions, Inc. $236.3506/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156075 CMS
Regeneron Healthcare Solutions, Inc. $106.9006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156062 CMS
Regeneron Healthcare Solutions, Inc. $228.9806/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156058 CMS
Exelixis Inc. $70.0006/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559698 CMS
Exelixis Inc. $70.0006/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559700 CMS
Exelixis Inc. $407.9806/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559712 CMS
Exelixis Inc. $400.3106/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559714 CMS
Exelixis Inc. $705.9606/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559724 CMS
Exelixis Inc. $18.3806/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559726 CMS
Exelixis Inc. $70.0006/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559732 CMS
Exelixis Inc. $10.5206/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559736 CMS
Exelixis Inc. $8.5506/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559738 CMS
Regeneron Healthcare Solutions, Inc. $279.7906/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156053 CMS
PFIZER INC. $446.8805/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813474 CMS
PFIZER INC. $32.7305/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813476 CMS
PFIZER INC. $16.0005/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813478 CMS
PFIZER INC. $5,125.0005/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813054 CMS
PFIZER INC. $64.4205/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813056 CMS
PFIZER INC. $472.9105/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813472 CMS
Regeneron Healthcare Solutions, Inc. $1,192.0004/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114156049 CMS
PFIZER INC. $4,150.0004/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131554141 CMS
PFIZER INC. $123.4004/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131552779 CMS
AstraZeneca Pharmaceuticals LP $90.3603/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104353650 CMS
Exelixis Inc. $4,455.0003/26/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559622 CMS
Exelixis Inc. $4,455.0003/26/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559676 CMS
Exelixis Inc. $30.0003/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559650 CMS
Exelixis Inc. $438.0103/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559628 CMS
Exelixis Inc. $294.0103/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559630 CMS
Exelixis Inc. $294.0103/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559690 CMS
Exelixis Inc. $438.0103/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559692 CMS
Astellas Pharma US Inc $18.1603/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139379152 CMS
Astellas Pharma US Inc $389.6803/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139384818 CMS
Astellas Pharma US Inc $4,380.0003/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387190 CMS
Astellas Pharma US Inc $744.4003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387192 CMS
Exelixis Inc. $4.6503/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559614 CMS
Exelixis Inc. $5.4103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559616 CMS
Exelixis Inc. $13.3503/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559618 CMS
Exelixis Inc. $22.4103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559620 CMS
Exelixis Inc. $16.0003/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559624 CMS
Exelixis Inc. $4.6503/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559678 CMS
Exelixis Inc. $5.4103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559680 CMS
Exelixis Inc. $13.3503/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559682 CMS
Exelixis Inc. $22.4103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559684 CMS
Exelixis Inc. $16.0003/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559686 CMS
Exelixis Inc. $4,620.0002/20/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559654 CMS
Exelixis Inc. $70.0002/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559626 CMS
Exelixis Inc. $373.2002/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559632 CMS
Exelixis Inc. $70.0002/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559688 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,495.36 80
PY2020 $24,611.93 18
PY2021 $64,727.06 57
PY2022 $89,425.26 100
PY2023 $190,120.01 233
PY2024 $90,134.59 121
PY2025 $57,957.21 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,846,455.57 15
PY2024 Principal investigator $320,227.97 27
PY2023 Principal investigator $2,274,426.25 42
PY2022 Recipient $3,200.00 1
PY2022 Principal investigator $1,292,533.65 18
PY2021 Recipient $3,200.00 1
PY2021 Principal investigator $48,082.24 19
PY2020 Recipient $219.00 1
PY2020 Principal investigator $233,268.37 50
PY2019 Recipient $127.33 1
PY2019 Principal investigator $380,695.55 94

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,545.73 12/31/2025 Non-covered Recipient Entity
CTRC at The University of Texas Health Science Center at San Antonio
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1232926197
Principal investigator 1 Merck Sharp & Dohme LLC $3,593,520.00 11/10/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
A Phase 1a,1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232936070
Principal investigator 1 Novartis Pharmaceuticals Corporation $130.86 10/27/2025 Non-covered Recipient Entity
UT HEALTH SAN ANTONIO MAYS CANCER CENTER
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190310797
Principal investigator 1 Merck Sharp & Dohme LLC $49,610.07 10/15/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232936212
Principal investigator 1 Gilead Sciences, Inc. $7,250.00 07/24/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212706
Principal investigator 1 Gilead Sciences, Inc. $294.75 07/18/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212700
Principal investigator 1 Merck Sharp & Dohme LLC $31,599.52 06/16/2025 Non-covered Recipient Entity
CTRC at The University of Texas Health Science Center at San Antonio
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1232926195
Principal investigator 1 Gilead Sciences, Inc. $294.75 06/13/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212717
Principal investigator 1 Gilead Sciences, Inc. $1,500.00 06/10/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212725
Principal investigator 1 Gilead Sciences, Inc. $5,935.61 05/02/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212744
Principal investigator 1 Gilead Sciences, Inc. $3,460.00 04/30/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212755
Principal investigator 1 Gilead Sciences, Inc. $19,984.05 03/05/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212736
Principal investigator 1 Novartis Pharmaceuticals Corporation $73,291.09 02/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190307421
Principal investigator 1 Gilead Sciences, Inc. $1,730.00 01/17/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1229212688
Principal investigator 1 Novartis Pharmaceuticals Corporation $52,309.14 01/12/2025 Non-covered Recipient Entity
UT HEALTH SAN ANTONIO MAYS CANCER CENTER
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190310799